The most consequential shift in European healthtech over the past three years has not happened at the top of the market. It has happened in the middle. The companies changing hands, returning capital to investors and giving founders their first real liquidity are not the unicorns that dominated conference stages in 2021. They are the $25M to $250M enterprise value businesses that quietly built revenue, won regulated customers and reached the point where a strategic buyer or a